Currently, studies using SSTR2 ligands for high-grade recurrent meningiomas are underway with the EORTC Brain Tumor Group network testing 177Lu-DOTATATE, as the study NCT03971461 has progressed to the second stage, but further research is crucial at this stage [120,148]. The gene discussed is SSTR2; the disease is meningioma.